Typical Ferritin Levels with Outpatient Ferrous Sulfate Maintenance Therapy
With outpatient oral ferrous sulfate maintenance therapy, ferritin levels typically remain quite low, generally in the range of 8-15 ng/mL, which is substantially below the target of ≥50 ng/mL needed to adequately replete iron stores and prevent iron deficiency. This represents a critical limitation of oral iron therapy that clinicians must recognize.
Evidence from Clinical Practice
The most compelling real-world data comes from a 2026 retrospective cohort study comparing oral ferrous sulfate to IV iron 1. After 3 months of oral ferrous sulfate treatment, patients achieved a mean ferritin of only 8.68 ± 4.38 µg/L (ng/mL), which remained well below the accepted threshold of ≥30 ng/mL for adequate iron store repletion. This stands in stark contrast to IV ferric carboxymaltose, which achieved ferritin levels of 412.60 ± 95.87 µg/L—approximately a 47-fold difference.
A 2012 study examining patients on proton pump inhibitors (which many outpatients take) showed even more concerning results 2. After 3 months of ferrous sulfate therapy, the mean ferritin increase was only 10.2 ± 7.8 µg/L, with only 40% of patients achieving a normal ferritin response (rise of >20 µg/dL). This suggests that in real-world outpatient settings where PPIs are common, oral iron performs even more poorly.
Why Oral Iron Achieves Such Low Ferritin Levels
The 2024 expert consensus guidelines explain that in the absence of inflammation, the goal ferritin should be ≥50 ng/mL regardless of sex 3. However, oral iron absorption is fundamentally limited—intestinal absorption decreases as iron stores increase, and absorption is further impaired by:
- Food intake (reduces absorption by up to 50%) 4
- Concurrent medications (especially PPIs and phosphate binders)
- Inflammatory conditions
- Hepcidin elevation (which occurs even with modest iron repletion)
Clinical Implications
This means that oral ferrous sulfate maintenance therapy typically maintains patients in a state of marginal iron sufficiency at best, with ferritin levels of 8-15 ng/mL that are inadequate for optimal erythropoiesis. The 2024 guidelines emphasize that hemoglobin should increase by 1-2 g/dL within 4-8 weeks of adequate iron therapy 3, but this often fails to occur with oral iron alone.
Common Pitfalls to Avoid:
Assuming oral iron is adequate based on hemoglobin alone - Patients may maintain borderline hemoglobin levels while remaining iron deficient (ferritin <50 ng/mL)
Not checking ferritin levels during oral iron therapy - The 2015 IBD guidelines recommend monitoring every 3 months initially 5, as recurrence is common
Continuing oral iron indefinitely without reassessment - If ferritin remains <30-50 ng/mL after 3 months of oral therapy, consider switching to IV iron
When Oral Iron May Be Acceptable
The 2015 European consensus on IBD suggests oral iron may be used in patients with 5:
- Mild anemia (Hb 11.0-12.9 g/dL in men, 11.0-11.9 g/dL in women)
- Clinically inactive disease
- No previous intolerance to oral iron
- Maximum dose of 100 mg elemental iron per day (not the traditional 200 mg)
However, even in these selected patients, ferritin levels typically remain suboptimal.
Practical Recommendation
For outpatient maintenance therapy, if you choose oral ferrous sulfate, expect ferritin levels of 8-15 ng/mL and plan to check ferritin at 3 months. If ferritin remains <50 ng/mL (or <100 ng/mL in patients with ongoing losses or inflammation), strongly consider transitioning to IV iron therapy, which consistently achieves ferritin levels of 200-400 ng/mL and provides superior iron store repletion 1, 3.
The 2001 KDOQI guidelines for CKD patients note that most hemodialysis patients require IV iron to maintain sufficient stores 4, and this principle increasingly applies to outpatients with ongoing iron losses or malabsorption who cannot achieve adequate ferritin levels with oral therapy alone.